Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
A6NNW6
UPID:
ENO4_HUMAN
Alternative names:
2-phospho-D-glycerate hydro-lyase
Alternative UPACC:
A6NNW6; A0A087WZY6; A6NI74; B8ZZN9; J3KNX1
Background:
Enolase 4, also known as 2-phospho-D-glycerate hydro-lyase, plays a crucial role in cellular processes, particularly in sperm motility and function. This protein's unique enzymatic activity is essential for energy production and cellular homeostasis, making it a key player in reproductive biology.
Therapeutic significance:
Understanding the role of Enolase 4 could open doors to potential therapeutic strategies. Its pivotal function in sperm motility and function highlights its importance in reproductive health, suggesting that targeting Enolase 4 could lead to novel treatments for male infertility.